Teva Pharmaceuticals has named Kaare Schultz as its new chief executive officer, ending a seven-month search.
Schultz, previously the the CEO of H. Lundbeck, will move to Israel and be based at Teva’s headquarters in Petach Tikva. He will replace Yitzhak Peterburg, who has been the acting CEO since February.
Former Teva leader, Erez Vigodman, resigned in February, as Teva struggled with a a series of costly missteps and controversies.
Read the Bloomberg coverage